Common Microbial Genital Infections and Their Impact on the Innate Immune Response to HPV in Cervical Cells.
CCL20
TLR9
genital infections
human papillomavirus
sexually transmitted infections
type III interferon
vaginosis
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
16 Nov 2022
16 Nov 2022
Historique:
received:
24
09
2022
revised:
10
11
2022
accepted:
14
11
2022
entrez:
24
11
2022
pubmed:
25
11
2022
medline:
25
11
2022
Statut:
epublish
Résumé
The persistence of high-risk (HR) human papillomavirus (HPV) genotypes is a prerequisite of cervical cancer. It is not clear whether and how bacterial vaginosis (BV) and sexually transmitted infections (STIs) cause higher rates of persistent HPV infection. This study aimed to characterize mucosal innate immunity to HPV, comparing different conditions. Specifically, expression levels of genes coding for Toll-like receptors (TLR)7 and 9, several type III Interferon-related genes (IFNL1, 2, 3, their specific receptor subunit IFNLR1, and the IFN-stimulated gene ISG15). Chemokines CCL5 and CCL20 were measured in cervical cells positive, or not, for HPV, BV, and STIs. HPV DNA was detected in 51/120 (42.5%) enrolled women, two/third were HR-HPV genotypes. More than 50% of samples were BV- and/or STI-positive. HPV-positive women had BV, but not other STIs, more frequently than the HPV-negative. TLR9 and IFNL1 mRNAs were expressed in the LR, but much less in the HR HPV infection. Enhanced levels of TLR9, TLR7, IFNL2, and IFNLR1 were observed in HPV-positive women with BV and STI. TLR9-increased expression was associated with HPV persistence in previous studies; hence, bacterial coinfections may enhance this risk. Prospective measurements of type III IFNs and IFNLR1 are warranted to evaluate whether this response may act as a double-edged sword in infected epithelia.
Identifiants
pubmed: 36422611
pii: pathogens11111361
doi: 10.3390/pathogens11111361
pmc: PMC9697853
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Ministry of University and Research: PRIN 2017
ID : 20179JHAMZ.
Références
J Leukoc Biol. 2005 Jul;78(1):158-66
pubmed: 15831560
Front Immunol. 2014 Aug 12;5:386
pubmed: 25161655
J Virol. 2005 Dec;79(23):14852-62
pubmed: 16282485
J Immunol. 2017 Nov 1;199(9):3270-3279
pubmed: 28954888
J Virol. 2020 Jun 1;94(12):
pubmed: 32295905
Int J Mol Sci. 2019 Mar 21;20(6):
pubmed: 30901970
Eur J Obstet Gynecol Reprod Biol. 2020 Feb;245:143-148
pubmed: 31901667
J Microbiol Immunol Infect. 2018 Apr;51(2):220-225
pubmed: 28711440
Nurs Clin North Am. 2019 Jun;54(2):207-225
pubmed: 31027662
PLoS Pathog. 2020 Mar 26;16(3):e1008376
pubmed: 32214382
Front Cell Infect Microbiol. 2020 Sep 25;10:569022
pubmed: 33102255
Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2215-2219
pubmed: 28681204
Genet Mol Res. 2015 Sep 08;14(3):10473-81
pubmed: 26400278
Immunobiology. 2015 Mar;220(3):363-8
pubmed: 25454809
Am J Reprod Immunol. 2014 Jun;71(6):555-63
pubmed: 24832618
Int J Mol Sci. 2019 Jan 11;20(2):
pubmed: 30641869
BMC Infect Dis. 2011 Jan 11;11:10
pubmed: 21223574
J Clin Virol. 2018 May;102:101-109
pubmed: 29549834
Front Cell Infect Microbiol. 2020 Mar 10;10:106
pubmed: 32211347
Mucosal Immunol. 2017 Sep;10(5):1310-1319
pubmed: 28120845
Clin Microbiol Rev. 2001 Oct;14(4):821-35, table of contents
pubmed: 11585787
Sex Transm Infect. 2014 Dec;90(8):580-7
pubmed: 25107710
Am J Obstet Gynecol. 2003 Mar;188(3):677-84
pubmed: 12634640
Front Immunol. 2022 May 18;13:857639
pubmed: 35663961
Nat Rev Immunol. 2001 Nov;1(2):135-45
pubmed: 11905821
Asian Pac J Cancer Prev. 2014;15(14):5867-72
pubmed: 25081715
Front Med (Lausanne). 2018 Jun 13;5:181
pubmed: 29951482
J Gynecol Oncol. 2009 Mar;20(1):39-43
pubmed: 19471662
Int J Immunopathol Pharmacol. 2011 Jan-Mar;24(1):217-23
pubmed: 21496405
Vaccine. 2006 Aug 31;24 Suppl 3:S3/52-61
pubmed: 16950018
J Clin Microbiol. 1991 Feb;29(2):297-301
pubmed: 1706728
BMC Infect Dis. 2009 Feb 12;9:16
pubmed: 19216747
Med Microbiol Immunol. 2014 Jun;203(3):177-84
pubmed: 24510368
J Immunol. 2007 Mar 1;178(5):3186-97
pubmed: 17312167
N Engl J Med. 2003 Feb 6;348(6):518-27
pubmed: 12571259
Clin Infect Dis. 2003 Aug 1;37(3):319-25
pubmed: 12884154
Front Immunol. 2019 Jul 16;10:1644
pubmed: 31379843
J Exp Med. 2020 Jan 6;217(1):
pubmed: 31821443
Int J Cancer. 2011 Feb 15;128(4):879-86
pubmed: 20473890
Int J Cancer. 2015 May 15;136(10):2402-8
pubmed: 25346143
Pathogens. 2020 Apr 17;9(4):
pubmed: 32316236
Immunity. 2019 Apr 16;50(4):907-923
pubmed: 30995506
Curr Opin Virol. 2021 Dec;51:106-110
pubmed: 34628358
PLoS Pathog. 2008 Mar 14;4(3):e1000017
pubmed: 18369468
J Virol. 2006 May;80(9):4501-9
pubmed: 16611910
J Clin Microbiol. 2012 Aug;50(8):2601-8
pubmed: 22622447
N Engl J Med. 2005 Nov 3;353(18):1899-911
pubmed: 16267321
Int J Cancer. 2018 Dec 1;143(11):2884-2891
pubmed: 30121951
Mol Carcinog. 2007 Nov;46(11):941-7
pubmed: 17440926